Romao Ema, Morales-Yanez Francisco, Hu Yaozhong, Crauwels Maxine, De Pauw Pieter, Hassanzadeh Gholamreza Ghassanzadeh, Devoogdt Nick, Ackaert Chloe, Vincke Cecile, Muyldermans Serge
Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
Curr Pharm Des. 2016;22(43):6500-6518. doi: 10.2174/1381612822666160923114417.
The discovery of functional heavy chain-only antibodies devoid of light chains in sera of camelids and sharks in the early nineties provided access to the generation of minimal-sized, single-domain, in vivo affinity-matured, recombinant antigenbinding fragments, also known as Nanobodies.
Recombinant DNA technology and adaptation of phage display vectors form the basis to construct large naïve, synthetic or medium sized immune libraries from where multiple Nanobodies have been retrieved. Alternative selection methods (i.e. bacterial display, bacterial two-hybrid, Cis-display and ribosome display) have also been developed to identify Nanobodies. The antigen affinity, stability, expression yields and structural details of the Nanobodies have been determined by standard technology. Nanobodies were subsequently engineered for higher stability and affinity, to have a sequence closer to that of human immunoglobulin domains, or to add designed effector functions.
Antigen specific Nanobodies recognizing with high affinity their cognate antigen were retrieved from various libraries. High expression yields are obtained from microorganisms, even when expressed in the cytoplasm. The purified Nanobodies are shown to possess beneficial biochemical and biophysical properties. The crystal structure of Nanobody::antigen complexes reveal the preference of Nanobodies for cavities on the antigen surface.
Thanks to the properties described above, Nanobodies became a highly valued and versatile tool for biomolecular research. Moreover, numerous diagnostic and therapeutic Nanobody-based applications have been developed in the past decade.
20世纪90年代初在骆驼科动物和鲨鱼血清中发现了不含轻链的功能性仅重链抗体,这使得人们能够产生最小尺寸的、单结构域的、体内亲和力成熟的重组抗原结合片段,即纳米抗体。
重组DNA技术和噬菌体展示载体的改造是构建大型天然、合成或中型免疫文库的基础,从中可以筛选出多种纳米抗体。还开发了其他筛选方法(如细菌展示、细菌双杂交、顺式展示和核糖体展示)来鉴定纳米抗体。纳米抗体的抗原亲和力、稳定性、表达产量和结构细节已通过标准技术确定。随后对纳米抗体进行工程改造,以提高其稳定性和亲和力,使其序列更接近人类免疫球蛋白结构域,或添加设计的效应功能。
从各种文库中筛选出了能高亲和力识别其同源抗原的抗原特异性纳米抗体。即使在细胞质中表达,微生物也能获得高表达产量。纯化后的纳米抗体显示出有益的生化和生物物理特性。纳米抗体::抗原复合物的晶体结构揭示了纳米抗体对抗原表面空腔的偏好。
由于上述特性,纳米抗体成为生物分子研究中一种非常有价值且用途广泛的工具。此外,在过去十年中已经开发了许多基于纳米抗体的诊断和治疗应用。